missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ LGI1 Polyclonal Antibody
Description
A suggested positive control is Hela cell lysate. PA5-20491 can be used with blocking peptide PEP-0611.
The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist.
Specifications
Specifications
| Antigen | LGI1 |
| Applications | Immunohistochemistry, Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% sodium azide |
| Gene | LGI1 |
| Gene Accession No. | O95970, Q8K4Y5, Q9JIA1 |
| Gene Alias | ADLTE; ADPAEF; ADPEAF; BB130740; EPITEMPIN; Epitempin 1; Epitempin-1; EPT; ETL1; IB1099; leucine rich glioma inactivated 1; leucine-rich glioma inactivated 1; leucine-rich glioma-inactivated protein 1; leucine-rich repeat LGI family, member 1; leucine-rich, glioma inactivated 1; LGI1; OTTHUMP00000020121; OTTHUMP00000020122; UNQ775/PRO1569 |
| Gene Symbols | LGI1 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?